Fig. 4: Validation of prognostic B-cell biomarkers. | npj Precision Oncology

Fig. 4: Validation of prognostic B-cell biomarkers.

From: Utilizing cohort-level and individual networks to predict best response in patients with metastatic triple negative breast cancer

Fig. 4

a Using the high/low threshold learned from the AMTEC cohort, mTNBC3s was able to significantly differentiate (P-value = 0.035; univariate CoxPH; n = 276) the CALGB patients based on event-free survival (EFS). Unfortunately, only 5 of the 34 genes in mTNBC3s were available in the METABRIC microarray expression dataset so it could not be screened directly. b However, the high/low threshold from mTNBC3s_top3 was further able to identify a 20 patient cohort with significantly lower overall survival (P-value = 0.001; logRank; n = 199) in Basal-classified samples from METABRIC.

Back to article page